June 14 (Reuters) – Eli Lilly and Co: * LILLY'S JAYPIRCA (PIRTOBRUTINIB) SIGNIFICANTLY REDUCED THE RISK OF DISEASE PROGRESSION OR DEATH BY 45% WHEN ADDED TO A VENETOCLAX TIME-LIMITED REGIMEN IN PEOPLE
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
Samsung Q2 profit jumps 19-fold as AI chip demand offsets mobile loss
SEOUL, July 30 (Reuters) - Samsung Electronics said on Thursday its operating profit jumped 19-fold…
De Minaur beats Tsitsipas as Fritz powers through in DC
VIDEO SHOWS: HIGHLIGHTS FROM DAY THREE OF THE THE WASHINGTON DC OPEN RESENDING WITH COMPLETE…
UPDATE 1-Singtel confirms talks with multiple parties over potential Optus stake sale
(Updates with details and background from paragraph 2 onwards) July 30 (Reuters) - Singapore Telecommunications…
